2026-06-27T22:30:17Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1324802026-02-18T01:02:06Zcom_20.500.14352_14col_20.500.14352_15

Guemes-Villahoz Noemi Talavero González Paula Porras-Ángel Paloma Bella Gala, Rafael Ruiz Pomeda, Alicia Martín García, Beatriz Hernández García, Elena GÓMEZ DE LIAÑO SALGADO, CARMEN NUNILA Shah Rakhee García Feijoo, Julián Gómez De Liaño Sánchez, María Rosario 2026-02-17T11:37:22Z 2026-02-17T11:37:22Z 2025-08-20 Guemes-Villahoz N, Talavero González P, Porras-Ángel P, Bella-Gala R, Ruiz-Pomeda A, Martin-Garcia B, Hernandez-Garcia E, Gomez de Liaño N, Shah R, Garcia-Feijoo J, Gomez-de-Liaño R. Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine. Br J Ophthalmol. 2025 Aug 20;109(9):1074-1080. doi: 10.1136/bjo-2024-326852. PMID: 40345841; PMCID: PMC12418587. 0007-1161 10.1136/bjo-2024-326852 https://hdl.handle.net/20.500.14352/132480 1468-2079 https://doi.org/10.1136/bjo-2024-326852 40345841 https://bjo.bmj.com/content/109/9/1074 Aim: To evaluate and compare the efficacy of combination treatment using 0.025% atropine and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses to 0.025% atropine and single vision (SV) spectacle lenses in slowing myopia progression in children with myopia. Methods: Randomised controlled trial conducted on children aged 4-16 years with myopia between -1.00D and -6.00D and astigmatism ≤2.00D. Children were randomly allocated into two groups: 0.025% atropine and SV spectacle lenses treatment group (group A), and 0.025% atropine and DIMS spectacle lenses treatment group (group B). Cycloplegic spherical equivalent refraction (SER) and axial length were measured at baseline, 6 and 12 months. Results: 102 patients completed the 12-month follow-up: n=49 in group A, mean age 9.50±2.78 years and n=53 in group B, mean age 9.90±2.47 years. At 12 months, the mean AL±SD change was 0.18±0.16 mm in group A and 0.07±0.16 mm in group B (mean difference: 0.11, 95% CI: 0.05 to 0.17; p≤0.001). Mean SER±SD progression at 12 months was -0.19±0.42D and -0.09±0.35D in groups A and B, respectively (p=0.13). 39.6% of children in group B had no axial elongation over 12 months compared with 12.2% of the children in group A (p=0.002). Conclusions: Combination treatment with 0.025% atropine and DIMS spectacle lenses is more effective in controlling axial elongation than 0.025% atropine with SV lenses. Although not significant, SER differences between groups were lower in group B. These findings support a potential additive effect of the two treatments. eng http://creativecommons.org/licenses/by-nc/4.0/ open access Attribution-NonCommercial 4.0 International Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine journal article